Ifosfamide Dosing in Hemodialysis Patients
Ifosfamide can be safely administered to patients on hemodialysis at standard doses (1.2 g/m²/day for 5 consecutive days), with hemodialysis performed after each dose to remove the drug and its toxic metabolites, thereby preventing neurotoxicity and other complications. 1, 2, 3
Dosing Strategy
Standard Dosing with Post-Infusion Hemodialysis
Use the FDA-approved standard dose of 1.2 g/m²/day for 5 consecutive days, repeated every 3 weeks or after hematologic recovery (platelets ≥100,000/μL, WBC ≥4,000/μL). 1
Schedule hemodialysis immediately after each ifosfamide infusion to actively remove the drug and its metabolites. Hemodialysis removes approximately 86.9% of parent ifosfamide, 77.2% of chloroacetaldehyde (the neurotoxic metabolite), and 36.2% of 4-hydroxyifosfamide. 2
The pharmacokinetics of parent ifosfamide may not be substantially altered in renal failure (Vd = 0.23 L/kg, t½ = 4.8 hours, ClT = 3.30 L/h/m²), making standard dosing feasible when combined with dialysis. 2
Critical Supportive Measures
Administer mesna at 60% of the ifosfamide dose using the all-IV three-bolus schedule: 20% given 15 minutes before ifosfamide, 20% at 4 hours, and 20% at 8 hours after infusion. 4
Provide vigorous hydration with at least 2 liters of oral or IV fluid per day to prevent bladder toxicity, even though urinary excretion is minimal in anuric patients. 1
Clinical Evidence Supporting Safety
Real-World Experience
Three patients with end-stage renal disease on hemodialysis were successfully treated with escalating doses of ifosfamide for metastatic sarcoma, with all patients showing clinical or radiographic therapeutic response. 3
Myelosuppression was the most common toxicity, but no patients developed life-threatening infections, neurotoxicity, or hematuria when hemodialysis was appropriately timed. 3
Hemodialysis rapidly reversed ifosfamide-related neurotoxicity when it occurred, with symptoms improving within hours of dialysis. 2
Critical Monitoring Requirements
Pre-Treatment Assessment
Obtain urinalysis before each dose; withhold ifosfamide if microscopic hematuria (>10 RBCs per high-power field) is present until complete resolution. 1
Check WBC count, platelet count, and hemoglobin before each administration; do not administer if WBC <2,000/μL or platelets <50,000/μL. 1
During Treatment
Monitor closely for neurologic manifestations (somnolence, confusion, hallucinations, coma), which require immediate discontinuation of ifosfamide and supportive care. 1
Severe myelosuppression is frequently observed, particularly when ifosfamide is combined with other chemotherapeutic agents, requiring close hematologic monitoring. 1
Important Caveats
The eGFR Value is Misleading
The stated eGFR of 39 mL/min/1.73 m² is irrelevant in a patient currently on hemodialysis, as this patient has end-stage renal disease with minimal to no residual kidney function. 3
All eGFR equations (MDRD, CKD-EPI, Cockcroft-Gault) are highly inaccurate in extreme clinical situations and should not guide dosing decisions in dialysis-dependent patients. 5, 6
Timing is Critical
The key to safety is performing hemodialysis after each ifosfamide dose, not dose reduction. The high extraction ratio (86.7%) during dialysis allows for standard dosing while preventing accumulation of toxic metabolites. 2
Administer ifosfamide as a slow IV infusion over a minimum of 30 minutes, followed by scheduled hemodialysis within hours to maximize drug removal. 1
Alternative Considerations
- If concerns about nephrotoxicity to any residual kidney function exist, cyclophosphamide may be substituted for ifosfamide in certain regimens, though this is based on limited evidence in different clinical contexts. 7